Form 4: Black Diamond Therapeutics CEO Receives Stock Options and Restricted Stock Units

Mark A. Velleca, CEO of Black Diamond Therapeutics, was granted stock options and restricted stock units (RSUs) on January 30, 2025, according to a Form 4 filing with the SEC.

Summary

• Mark A. Velleca, the President and CEO of Black Diamond Therapeutics, Inc., received a grant of 75,000 Restricted Stock Units (RSUs) and options to purchase 500,000 shares of common stock on January 30, 2025.
• The RSUs vest in two tranches: 50% on January 30, 2026, and the remaining 50% on January 30, 2027, contingent upon continued service.
• The stock options have an exercise price of $2.52 per share.
• 25% of the stock options vest on January 30, 2026, with the remaining options vesting in 36 equal monthly installments thereafter, also contingent upon continued service.
• Following these transactions, Velleca directly owns 121,522 shares of common stock and options to purchase 500,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of equity suggests confidence in the CEO's ability to drive future value, but it's a routine transaction.

Positives

• The grant of RSUs and stock options aligns the CEO's interests with those of the shareholders, incentivizing him to increase the company's value.
• The vesting schedules for both the RSUs and stock options encourage long-term commitment from the CEO.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the equity grants suggest an expectation of continued service and, presumably, positive performance from the CEO.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain top executive talent. The size and structure of the grants are likely benchmarked against peer companies to ensure competitiveness.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation tools for executives in the biotech industry.
• Companies like Amgen, Gilead, and Regeneron routinely use similar equity-based compensation packages.
• The vesting schedules (25% after one year, then monthly) are fairly typical, aligning with industry norms for incentivizing long-term performance.

Stakeholder Impact

• Shareholders: The equity grants align the CEO's interests with shareholder value creation.
• Employees: The grants can boost morale by demonstrating the company's commitment to its leadership.

Key Dates